279 related articles for article (PubMed ID: 22833573)
1. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.
Huehls AM; Wagner JM; Huntoon CJ; Geng L; Erlichman C; Patel AG; Kaufmann SH; Karnitz LM
Cancer Res; 2011 Jul; 71(14):4944-54. PubMed ID: 21613406
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Geng L; Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
PLoS One; 2011; 6(12):e28862. PubMed ID: 22194930
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
Joshi PM; Sutor SL; Huntoon CJ; Karnitz LM
J Biol Chem; 2014 Mar; 289(13):9247-53. PubMed ID: 24554720
[TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
9. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
10. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Shibata H; Miuma S; Saldivar JC; Huebner K
Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
[TBL] [Abstract][Full Text] [Related]
11. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant.
Bauer M; Goldstein M; Heylmann D; Kaina B
PLoS One; 2012; 7(6):e39956. PubMed ID: 22768182
[TBL] [Abstract][Full Text] [Related]
12. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
13. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Davidson D; Wang Y; Aloyz R; Panasci L
Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
Clark CC; Weitzel JN; O'Connor TR
Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
[TBL] [Abstract][Full Text] [Related]
15. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
16. A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Alagpulinsa DA; Ayyadevara S; Yaccoby S; Shmookler Reis RJ
Mol Cancer Ther; 2016 Feb; 15(2):241-50. PubMed ID: 26719576
[TBL] [Abstract][Full Text] [Related]
17. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
18. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
19. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
20. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]